RIKEN Center for Life Science Technologies


  • Research

    Latest publications from CLST.
  • News

    Awards, agreements, and other news.
  • Events

    Upcoming and past events including seminars, symposiums, open days.

For Public

To let you know about our research, this area contains 4 types of information about CLST; “Article”, “Videos”, “Event” and “Study”.
At “Article”, you can read articles on interviews and lectures, and you can enjoy the videos about CLST at “Videos”. If you want to meet and talk directly with the researcher, “Visit” give you some information of such events. You can find more difficult contents to know about our research deeply at “Study”.
  • Article
  • Event
  • Videos
  • Study

Technologies of CLST

Technique to detect tissue fibrogenesis using the antibodies against TGF-β LAP degradation products



 The most fibrogenic cytokine, TGF-β, is produced as a latent complex, in which active TGF-β is wrapped by latency associated protein (LAP), preventing TGF-β from binding its receptor on target cells. Therefore, active TGF-β must be released from latent complexto exert biological activities (TGF-β activation reaction). We elucidated that plasma kallikrein cleaves LAP between R58 and L59 residues and activates TGF-β in the pathogenesis of liver fibrosis. To detect degradated products of LAP (LAP-DPs), we produced two specific antibodies. One is the R58 antibody detecting N-terminal side LAP-DPs terminating on R58 residue (R58 LAP-DPs), and another is L59 antibody detecting C-terminal side LAP-DPs starting from L59 residue (L59 LAP-DPs). We established techniques to detect each LAP-DPs using the antibodies. The R58 LAP-DPs remaining in tissues or cell surfaces through S-S bonded LTBP can be detected by immunostaining with the R58 antibody, whereas the L59 LAP-DPs released into blood can be measured by the ELISA using the L59 antibody. These LAP-DPs can be a surrogate biomarker of TGF-ß activation and subsequent fibrogenesis.

Figure : The LAP-DPs, which are by-products of PLK-dependent TGF-β activation reaction, can be detected by immunostaining with the R58 antibody or by an ELISA using the L59 antibody. LAP-DPs can be surrogate biomarkers of TGF-β activation and subsequent fibrogenesis.


  1. LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis, Hara M., Kirita A., Kondo W. et al. Springerplus. May 1; 3: 221. PMID: 24877031 (2014)

Related labs

CLST was reorganized into three centers according to the RIKEN 4th Medium-Term Plan from April 1, 2018.